⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALT News
Altimmune, Inc. Common Stock
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Form 8-K
sec.gov
ALT
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
globenewswire.com
ALT
Hybrid Fiber Coaxial (HFC) Market Size to Hit USD 26.97 Billion by 2035 | Research by SNS Insider
globenewswire.com
CMCSA
CHTR
ALT
Advancements in AUD Treatment: Precision Therapies and Future Growth Projections
globenewswire.com
ADIL
ALKS
LLY
ALT
Form 8-K
sec.gov
ALT
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
globenewswire.com
ALT
Altimmune to Participate in Upcoming Investor Conferences
globenewswire.com
ALT
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
globenewswire.com
ALT
Altimetrik Recognized in 3 Categories in ISG Provider Lens™ 2026 for Life Sciences Digital Services
businesswire.com
ALT